Tests ecnoglutide injection in overweight or obese Chinese teenagers
Tests an injection called ecnoglutide against a placebo in teenagers with obesity.
Plain-language title generated from the registry record
Registry title: A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Source: NCT07836270, who can take part
Where in China
- Children's Hospital, Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hangzhou Sciwind Biosciences Co., Ltd.
- Trial code
- NCT07836270
- Record updated
- 23 September 2026
- Original description
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescentsRead full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Safety and Efficacy of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents (SLIMMER-YOUNG)
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
Inclusion: At screening, the BMI meets the obesity criteria specified in 'WS/T586-2018 Screening for Overweight and Obesity in School-Aged Children and Adolescents', or it meets the overweight criteria and is accompanied by at least one weight-related comorbidity: hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, etc; Participant with body weight loss <5% by diet and exercise for at least 3 months before screening (per self, parental/legal report).
Exclusion: History of receiving weight loss surgery or plan to undergo weight loss surgery during the study period (excluding acupuncture-based weight loss, liposuction, or abdominal fat removal procedures conducted more than 1 year prior to screening); History of using any approved or unapproved drugs for weight loss, antidiabetic drugs, long-term systemic glucocorticoids (more than 14 days), within 3 months prior to screening; Known secondary obesity, including but not limited to that resulting from: hypercortisolism (e.g. Cushing's syndrome), pituitary or hypothalamic lesions, or monogenic obesity, etc; Diagnosis with any type of diabetes; History of acute or chronic pancreatitis, history of gallbladder disease or pancreatic injury; Pre-adolescent participants (Tanner phase 1).